GSK to sell anti-rabies vaccines Rabipur, Encepur to Bavarian Nordic for USD 1.1 billion
The sale of GSK's anti-rabies treatment Rabipur and Encepur, used for the prevention of tick-borne encephalitis, to the Denmark-based biotechnology firm includes an upfront payment of 301 million euros and milestone payments of up to 495 million euros.
New Delhi: GlaxoSmithKline will sell two travel vaccines to Bavarian Nordic for up to 955 million euros ($1.1 billion), the British firm said on Monday, as it looks to bolster its push into the lucrative cancer drug market.
The sale of anti-rabies treatment Rabipur and Encepur, used for the prevention of tick-borne encephalitis, to the Denmark-based biotechnology firm includes an upfront payment of 301 million euros and milestone payments of up to 495 million euros.
Chief Executive Officer Emma Walmsley has been pushing for a leaner structure since she took over in 2017 by spinning off or selling units to focus on reinvigorating GSK's pharmaceuticals business. It staged a comeback into cancer treatments with a $5.1 billion buyout of U.S. drugmaker Tesaro in December last year.
"This agreement with Bavarian Nordic will enable us to commit greater resources to our key growth assets and to our R&D pipeline," Roger Connor, president of Global Vaccines at GSK said.
Read Also: GSK collaborates with Lyell Immunopharma on cancer cell therapies
GSK, which is preparing to separate its consumer-facing products and drug businesses, acquired the vaccines from Novartis in 2015 as part of a broad asset-swap in which GSK sold its oncology business to the Swiss drugmaker.
The drugmaker reported revenue of 5.89 billion pounds ($7.61 billion) from its vaccines segment in 2018.
London-listed GSK said that both vaccines will continue to be manufactured at its Marburg site in Germany until full production is transferred to Bavarian Nordic within five years.
Read Also: Amid cancer scares GSK recalls heartburn drug Zantac as a precautionary measure
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd